González-Álvaro Isidoro, Martínez-Fernández Carmen, Dorantes-Calderón Benito, García-Vicuña Rosario, Hernández-Cruz Blanca, Herrero-Ambrosio Alicia, Ibarra-Barrueta Olatz, Martín-Mola Emilio, Monte-Boquet Emilio, Morell-Baladrón Alberto, Sanmartí Raimon, Sanz-Sanz Jesús, de Toro-Santos Francisco Javier, Vela Paloma, Román Ivorra José Andrés, Poveda-Andrés José Luis, Muñoz-Fernández Santiago
Rheumatology Service, Instituto de Investigación Sanitaria La Princesa, Hospital Universitario de La Princesa, Madrid, Research Unit, Spanish Rheumatology Society, Madrid, Hospital Pharmacy Clinical Management Unit, Hospital de Valme, Seville, Rheumatology Clinical Management Unit, Hospital Universitario Virgen Macarena, Seville, Hospital Pharmacy Service, Hospital Universitario La Paz, IdiPaz, Madrid, Hospital Pharmacy Service, Hospital de Galdakano-Usansolo, Vizcaya, Rheumatology Service, Hospital Universitario La Paz, IdiPaz, Universidad Autónoma de Madrid, Madrid, Hospital Pharmacy Service, Hospital Universitari i Politécnic La Fe, Valencia, Hospital Pharmacy Service, Hospital Universitario de La Princesa, Madrid, Rheumatology Service, Hospital Clinic de Barcelona, Universidad de Barcelona, Barcelona, Rheumatology Service, Hospital Puerta de Hierro, Madrid, Rheumatology Service, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña (CHUAC), Sergas. Universidade da Coruña, A Coruña, Rheumatology Section, Hospital General Universitario de Alicante, Universidad Miguel Hernández, Alicante, Rheumatology Service, Hospital Universitari i Politécnic La Fe, Valencia andRheumatology Service, Hospital Universitario Infanta Sofía, Universidad Europea de Madrid, Spain
Rheumatology Service, Instituto de Investigación Sanitaria La Princesa, Hospital Universitario de La Princesa, Madrid, Research Unit, Spanish Rheumatology Society, Madrid, Hospital Pharmacy Clinical Management Unit, Hospital de Valme, Seville, Rheumatology Clinical Management Unit, Hospital Universitario Virgen Macarena, Seville, Hospital Pharmacy Service, Hospital Universitario La Paz, IdiPaz, Madrid, Hospital Pharmacy Service, Hospital de Galdakano-Usansolo, Vizcaya, Rheumatology Service, Hospital Universitario La Paz, IdiPaz, Universidad Autónoma de Madrid, Madrid, Hospital Pharmacy Service, Hospital Universitari i Politécnic La Fe, Valencia, Hospital Pharmacy Service, Hospital Universitario de La Princesa, Madrid, Rheumatology Service, Hospital Clinic de Barcelona, Universidad de Barcelona, Barcelona, Rheumatology Service, Hospital Puerta de Hierro, Madrid, Rheumatology Service, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña (CHUAC), Sergas. Universidade da Coruña, A Coruña, Rheumatology Section, Hospital General Universitario de Alicante, Universidad Miguel Hernández, Alicante, Rheumatology Service, Hospital Universitari i Politécnic La Fe, Valencia andRheumatology Service, Hospital Universitario Infanta Sofía, Universidad Europea de Madrid, Spain.
Rheumatology (Oxford). 2015 Jul;54(7):1200-9. doi: 10.1093/rheumatology/keu461. Epub 2014 Dec 19.
The aim of this study was to establish guidelines for the optimization of biologic therapies for health professionals involved in the management of patients with RA, AS and PsA.
Recommendations were established via consensus by a panel of experts in rheumatology and hospital pharmacy, based on analysis of available scientific evidence obtained from four systematic reviews and on the clinical experience of panellists. The Delphi method was used to evaluate these recommendations, both between panellists and among a wider group of rheumatologists.
Previous concepts concerning better management of RA, AS and PsA were reviewed and, more specifically, guidelines for the optimization of biologic therapies used to treat these diseases were formulated. Recommendations were made with the aim of establishing a plan for when and how to taper biologic treatment in patients with these diseases.
The recommendations established herein aim not only to provide advice on how to improve the risk:benefit ratio and efficiency of such treatments, but also to reduce variability in daily clinical practice in the use of biologic therapies for rheumatic diseases.
本研究旨在为参与类风湿关节炎(RA)、强直性脊柱炎(AS)和银屑病关节炎(PsA)患者管理的卫生专业人员制定生物治疗优化指南。
风湿病学和医院药学专家小组基于对四项系统评价获得的现有科学证据的分析以及小组成员的临床经验,通过共识制定了建议。采用德尔菲法在小组成员之间以及更广泛的风湿病学家群体中评估这些建议。
回顾了以往关于RA、AS和PsA更好管理的概念,更具体地说,制定了用于治疗这些疾病的生物治疗优化指南。提出这些建议的目的是制定一个计划,以确定何时以及如何逐步减少这些疾病患者的生物治疗。
本文制定的建议不仅旨在就如何提高此类治疗的风险效益比和效率提供建议,还旨在减少风湿性疾病生物治疗日常临床实践中的变异性。